177 related articles for article (PubMed ID: 36198542)
1. [Treatment strategies for multiple myeloma based on molecular pathogenesis].
Furukawa Y
Rinsho Ketsueki; 2022; 63(9):1167-1179. PubMed ID: 36198542
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of clonal evolution in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2020 Apr; 111(4):496-511. PubMed ID: 32026210
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis of multiple myeloma.
Furukawa Y; Kikuchi J
Int J Clin Oncol; 2015 Jun; 20(3):413-22. PubMed ID: 25953678
[TBL] [Abstract][Full Text] [Related]
4. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
Heider M; Nickel K; Högner M; Bassermann F
Oncol Res Treat; 2021; 44(12):672-681. PubMed ID: 34749378
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response.
Abdallah N; Rajkumar SV; Greipp P; Kapoor P; Gertz MA; Dispenzieri A; Baughn LB; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Bergsagel L; Ketterling R; Kumar SK
Blood Cancer J; 2020 Aug; 10(8):82. PubMed ID: 32782240
[TBL] [Abstract][Full Text] [Related]
6. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.
Melchor L; Brioli A; Wardell CP; Murison A; Potter NE; Kaiser MF; Fryer RA; Johnson DC; Begum DB; Hulkki Wilson S; Vijayaraghavan G; Titley I; Cavo M; Davies FE; Walker BA; Morgan GJ
Leukemia; 2014 Aug; 28(8):1705-15. PubMed ID: 24480973
[TBL] [Abstract][Full Text] [Related]
7. Evolutionary biology of high-risk multiple myeloma.
Pawlyn C; Morgan GJ
Nat Rev Cancer; 2017 Aug; 17(9):543-556. PubMed ID: 28835722
[TBL] [Abstract][Full Text] [Related]
8. [Molecular Mechanism and Malignant Clonal Evolution of Multiple Myeloma].
Ding F; Zhu P; Wu XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1513-6. PubMed ID: 26524068
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.
Schmidt-Hieber M; Gutiérrez ML; Pérez-Andrés M; Paiva B; Rasillo A; Tabernero MD; Sayagués JM; Lopez A; Bárcena P; Sanchez ML; Gutiérrez NC; San Miguel JF; Orfao A
Haematologica; 2013 Feb; 98(2):279-87. PubMed ID: 22929983
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.
Noonan K; Colson K
Semin Oncol Nurs; 2017 Aug; 33(3):279-291. PubMed ID: 28666621
[TBL] [Abstract][Full Text] [Related]
11. Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma.
Suzuki K; Nishiwaki K; Yano S
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435539
[TBL] [Abstract][Full Text] [Related]
12. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
Gralewski JH; Post GR; van Rhee F; Yuan Y
Diagn Pathol; 2018 Feb; 13(1):15. PubMed ID: 29463311
[TBL] [Abstract][Full Text] [Related]
13. The Tao of myeloma.
Boise LH; Kaufman JL; Bahlis NJ; Lonial S; Lee KP
Blood; 2014 Sep; 124(12):1873-9. PubMed ID: 25097176
[TBL] [Abstract][Full Text] [Related]
14. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.
Ziccheddu B; Biancon G; Bagnoli F; De Philippis C; Maura F; Rustad EH; Dugo M; Devecchi A; De Cecco L; Sensi M; Terragna C; Martello M; Bagratuni T; Kastritis E; Dimopoulos MA; Cavo M; Carniti C; Montefusco V; Corradini P; Bolli N
Blood Adv; 2020 Mar; 4(5):830-844. PubMed ID: 32126144
[TBL] [Abstract][Full Text] [Related]
15. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
[TBL] [Abstract][Full Text] [Related]
16. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.
Pawlyn C; Melchor L; Murison A; Wardell CP; Brioli A; Boyle EM; Kaiser MF; Walker BA; Begum DB; Dahir NB; Proszek P; Gregory WM; Drayson MT; Jackson GH; Ross FM; Davies FE; Morgan GJ
Blood; 2015 Jan; 125(5):831-40. PubMed ID: 25428216
[TBL] [Abstract][Full Text] [Related]
17. A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration.
Schürch CM; Rasche L; Frauenfeld L; Weinhold N; Fend F
Virchows Arch; 2020 Mar; 476(3):337-351. PubMed ID: 31848687
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of multiple myeloma.
Dolloff NG; Talamo G
Adv Exp Med Biol; 2013; 779():197-221. PubMed ID: 23288641
[TBL] [Abstract][Full Text] [Related]
19. Branching clonal evolution patterns predominate mutational landscape in multiple myeloma.
Farswan A; Jena L; Kaur G; Gupta A; Gupta R; Rani L; Sharma A; Kumar L
Am J Cancer Res; 2021; 11(11):5659-5679. PubMed ID: 34873486
[TBL] [Abstract][Full Text] [Related]
20. Molecular and immunological mechanisms of clonal evolution in multiple myeloma.
Forster S; Radpour R; Ochsenbein AF
Front Immunol; 2023; 14():1243997. PubMed ID: 37744361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
